CLINICAL TRIAL: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE I

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 索拉非尼治疗将导致儿童难治性实体瘤的抗肿瘤活性。确定难治性实体瘤儿童口服索拉非尼（索拉非尼）片剂的最大耐受剂量（MTD）和推荐II期剂量，BID约每12小时一次，28天为一个周期，周期之间无停药期;并确定难治性白血病儿童是否耐受实体瘤MTD。定义并描述索拉非尼BID口服给药（约每12小时一次）的毒性，每28天为一个周期，周期之间无停药期。描述索拉非尼在难治性实体瘤或白血病儿童中的药代动力学特征。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Treatment with Sorafenib will result in anti-tumor activity in children with refractory solid tumors. Determine the maximum tolerated dose (MTD) and recommended phase II dose of Sorafenib (sorafenib) administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors; and to determine whether children with refractory leukemia tolerate the solid tumor MTD. Define and describe the toxicities of Sorafenib administered orally BID (approximately every 12 hours) for cycles of 28 days with no rest period between cycles. Characterize the pharmacokinetics of Sorafenib in children with refractory solid tumors or leukemias.